March 24, 2010 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy."There is a need for better tolerated, more effective therapies for narcolepsy, especially narcolepsy with cataplexy,"... Arena Pharmaceuticals' Press Release -
